Lithium's emerging role in the treatment of refractory major depressive episodes: augmentation of antidepressants - PubMed (original) (raw)
Review
doi: 10.1159/000314308. Epub 2010 May 7.
Affiliations
- PMID: 20453533
- DOI: 10.1159/000314308
Free article
Review
Lithium's emerging role in the treatment of refractory major depressive episodes: augmentation of antidepressants
Michael Bauer et al. Neuropsychobiology. 2010.
Free article
Abstract
Background: The late onset of therapeutic response and a relatively large proportion of nonresponders to antidepressants remain major concerns in clinical practice. Therefore, there is a critical need for effective medication strategies that augment treatment with antidepressants.
Methods: To review the available evidence on the use of lithium as an augmentation strategy to treat depressive episodes.
Results: More than 30 open-label studies and 10 placebo-controlled double-blind trials have demonstrated substantial efficacy of lithium augmentation in the acute treatment of depressive episodes. Most of these studies were performed in unipolar depression and included all major classes of antidepressants, however mostly tricyclics. A meta-analysis including 10 randomized placebo-controlled trials has provided evidence that lithium augmentation has a statistically significant effect on the response rate compared to placebo with an odds ratio of 3.11, which corresponds to a number-needed-to-treat of 5. The meta-analysis revealed a mean response rate of 41.2% in the lithium group and 14.4% in the placebo group. One placebo-controlled trial in the continuation treatment phase showed that responders to acute-phase lithium augmentation should be maintained on the lithium-antidepressant combination for at least 12 months to prevent early relapses. Preliminary studies to assess genetic influences on response probability to lithium augmentation have suggested a predictive role of the -50T/C single nucleotide polymorphism of the GSK3beta gene.
Conclusion: Augmentation of antidepressants with lithium is currently the best-evidenced augmentation therapy in the treatment of depressed patients who do not respond to antidepressants.
Copyright 2010 S. Karger AG, Basel.
Similar articles
- Lithium augmentation in treatment-resistant depression: clinical evidence, serotonergic and endocrine mechanisms.
Bschor T, Lewitzka U, Sasse J, Adli M, Köberle U, Bauer M. Bschor T, et al. Pharmacopsychiatry. 2003 Nov;36 Suppl 3:S230-4. doi: 10.1055/s-2003-45135. Pharmacopsychiatry. 2003. PMID: 14677084 Review. - Lithium augmentation therapy in refractory depression-update 2002.
Bauer M, Forsthoff A, Baethge C, Adli M, Berghöfer A, Döpfmer S, Bschor T. Bauer M, et al. Eur Arch Psychiatry Clin Neurosci. 2003 Jun;253(3):132-9. doi: 10.1007/s00406-003-0430-9. Eur Arch Psychiatry Clin Neurosci. 2003. PMID: 12904977 Review. - Role of lithium augmentation in the management of major depressive disorder.
Bauer M, Adli M, Ricken R, Severus E, Pilhatsch M. Bauer M, et al. CNS Drugs. 2014 Apr;28(4):331-42. doi: 10.1007/s40263-014-0152-8. CNS Drugs. 2014. PMID: 24590663 Review. - Mood stabilizer augmentation in apparently "unipolar" MDD: predictors of response in the naturalistic French national EPIDEP study.
Hantouche EG, Akiskal HS, Lancrenon S, Chatenêt-Duchêne L. Hantouche EG, et al. J Affect Disord. 2005 Feb;84(2-3):243-9. doi: 10.1016/j.jad.2004.01.006. J Affect Disord. 2005. PMID: 15708422 - Lithium augmentation therapy in refractory depression: clinical evidence and neurobiological mechanisms.
Bauer M, Adli M, Baethge C, Berghöfer A, Sasse J, Heinz A, Bschor T. Bauer M, et al. Can J Psychiatry. 2003 Aug;48(7):440-8. doi: 10.1177/070674370304800703. Can J Psychiatry. 2003. PMID: 12971013 Review.
Cited by
- Polygenic risk scores of lithium response and treatment resistance in major depressive disorder.
Xiong Y, Karlsson R, Song J, Kowalec K, Rück C, Sigström R, Jonsson L, Clements CC, Andersson E, Boberg J, Lewis CM, Sullivan PF, Landén M, Lu Y. Xiong Y, et al. Transl Psychiatry. 2023 Sep 28;13(1):301. doi: 10.1038/s41398-023-02602-3. Transl Psychiatry. 2023. PMID: 37770441 Free PMC article. - Lithium Therapy in Old Age: Recommendations from a Delphi Survey.
Christl J, Müller-Oerlinghausen B, Bauer M, Kamp D, Fußer F, Benninghoff J, Fehrenbach RA, Lange-Asschenfeldt C, Rapp M, Ibach B, Schaub R, Wollmer A, Strotmann-Tack T, Hüll M, Biermann S, Roscher K, Meissnest B, Menges A, Weigel B, Maliszewski-Makowka D, Mauerer C, Schaefer M, Joachimsmeier B, Kayser S, Rump LC, Supprian T. Christl J, et al. Pharmacopsychiatry. 2023 Sep;56(5):188-196. doi: 10.1055/a-2117-5200. Epub 2023 Jul 28. Pharmacopsychiatry. 2023. PMID: 37506737 Free PMC article. - Plausible Role of Stem Cell Types for Treating and Understanding the Pathophysiology of Depression.
Sachdeva P, Ji S, Ghosh S, Ghosh S, Raghunath M, Kim H, Bhaskar R, Sinha JK, Han SS. Sachdeva P, et al. Pharmaceutics. 2023 Mar 2;15(3):814. doi: 10.3390/pharmaceutics15030814. Pharmaceutics. 2023. PMID: 36986674 Free PMC article. Review. - Investigating genetic overlap between antidepressant and lithium response and treatment resistance in major depressive disorder.
Lu Y, Xiong Y, Karlsson R, Song J, Kowalec K, Rück C, Sigstrom R, Jonsson L, Clements C, Andersson E, Boberg J, Lewis C, Sullivan P, Landén M. Lu Y, et al. Res Sq [Preprint]. 2023 Feb 20:rs.3.rs-2556941. doi: 10.21203/rs.3.rs-2556941/v1. Res Sq. 2023. PMID: 36865283 Free PMC article. Updated. Preprint. - Calcium-Dependent Interplay of Lithium and Tricyclic Antidepressants, Amitriptyline and Desipramine, on _N_-methyl-D-aspartate Receptors.
Boikov SI, Sibarov DA, Stepanenko YD, Karelina TV, Antonov SM. Boikov SI, et al. Int J Mol Sci. 2022 Dec 19;23(24):16177. doi: 10.3390/ijms232416177. Int J Mol Sci. 2022. PMID: 36555818 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources